CC
NMRA icon

Callan Capital’s Neumora Therapeutics NMRA Stock Holding History

Callan Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$639K Buy
638,784
+2,590
+0.4% +$4.43K 0.05% 171
2024
Q4 		$6.74M Sell
636,194
-25,000
-4% -$300K 0.49% 41
2024
Q3 		$8.73M Hold
661,194
– – 0.61% 30
2024
Q2 		$6.5M Buy
661,194
+456,207
+223% +$4.72M 0.53% 37
2024
Q1 		$2.82M Buy
+204,987
New +$3.31M 0.25% 56

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Callan Capital's NMRA Position: Q1 2025 in Review

Callan Capital increased its Neumora Therapeutics (NMRA) stake by 0.41% in Q1 2025, buying an estimated $4.43K and bringing the position to 638,784 shares worth $639K. The position accounts for 0.05% of the portfolio, ranked #171.

Callan Capital first reported a position in NMRA in Q1 2024 and has held it in 5 quarters since. The position peaked at $8.73M in Q3 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Callan Capital held 638,784 shares of Neumora Therapeutics worth $639K as of Q1 2025.
  • Callan Capital bought 2,590 Neumora Therapeutics shares in Q1 2025, an estimated $4.43K.
  • Neumora Therapeutics made up 0.05% of Callan Capital's portfolio in Q1 2025, its #171 holding.
  • Callan Capital first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Callan Capital's Neumora Therapeutics position peaked at $8.73M in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.